Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $36.15M
Last updated: Nov 17, 2026 at 11:04 AM ET
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Stock Forecast
Analysts expect Telomir Pharmaceuticals, Inc. Common Stock (TELO) to earn -$0.11 per share in the fiscal year ending Dec 31, 2026. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.17.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending Dec 31, 2026
- -$0.11
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.17
- EPS consensus
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.11 | -$0.11 to -$0.11 | 1 |
| Dec 31, 2027 | -$0.17 | -$0.17 to -$0.17 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Mar 31, 2027 | -$0.04 | -$0.04 to -$0.04 | 1 |
Estimate Revisions
No EPS estimate for the 3 periods below was revised in the last 30 days.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
Frequently Asked Questions About TELO
What is the TELO stock forecast?
Consensus analyst estimates put Telomir Pharmaceuticals, Inc. Common Stock's EPS at -$0.11 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from TELO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.11, with estimates from -$0.11 to -$0.11 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.17, with estimates from -$0.17 to -$0.17 from 1 analyst.
How many analysts cover TELO?
1 analyst estimates EPS for Telomir Pharmaceuticals, Inc. Common Stock for the fiscal year ending Dec 31, 2026.
TELO pages: Overview, Forecast, Financials, Competitors